Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 7/20 | 0.76 |
| ▸ | FGF2 | P09038 | 4/20 | 0.76 |
| ▸ | HPSE | Q9Y251 | 14/20 | 0.61 |
| ▸ | SERPINC1 | P01008 | 2/20 | 0.54 |
| ▸ | VEGFA | P15692 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18742104 | 1.00 | FGF1 (0.76) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL7311357 | 1.00 | FGF1 (0.76) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL14020073 | 0.95 | FGF1 (0.70) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL4904646 | 0.95 | FGF1 (0.70) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL4906384 | 0.95 | FGF1 (0.70) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL4180806 | 0.92 | FGF1 (0.69) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL14020078 | 0.90 | FGF1 (0.64) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL14020074 | 0.90 | FGF1 (0.64) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL14020081 | 0.90 | FGF1 (0.64) | FGF1FGF2HPSESERPINC1VEGFA | |
| SCHEMBL16316488 | 0.90 | FGF1 (0.64) | FGF1FGF2HPSESERPINC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647126-A2 | STABILIZING CAMPTOTHECIN PHARMACEUTICAL COMPOSITIONS | Ipsen Biopharm Ltd. (GB) | 2025-11-12 | — | — | EP | disclosed |
| US-20250152578-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2025-05-15 | — | — | US | disclosed |
| US-20250000796-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2025-01-02 | — | — | US | disclosed |
| US-12059497-B2 | Stabilizing camptothecin pharmaceutical compositions | IPSEN BIOPHARM LTD. (GB) | 2024-08-13 | — | — | US | disclosed |
| US-20230108934-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2023-04-06 | — | — | US | disclosed |
| CN-114099437-A | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114073678-A | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-108366965-B | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210228567-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2021-07-29 | — | — | US | disclosed |
| US-20210205219-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2021-07-08 | — | — | US | disclosed |
| US-20200179371-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20200069586-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2020-03-05 | — | — | US | disclosed |
| US-10456360-B2 | Stabilizing camptothecin pharmaceutical compositions | IPSEN BIOPHARM LTD. (GB) | 2019-10-29 | — | — | US | disclosed |
| US-20190262331-A9 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2019-08-29 | — | — | US | disclosed |
| US-20190105317-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2019-04-11 | — | — | US | disclosed |
| US-20180296484-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | IPSEN BIOPHARM LTD. (GB) | 2018-10-18 | — | — | US | disclosed |
| EP-3362049-A1 | STABILIZING CAMPTOTHECIN PHARMACEUTICAL COMPOSITIONS | Ipsen Biopharm Ltd. (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-20180110771-A1 | Liposomal Irinotecan Preparations | IPSEN BIOPHARM LTD (GB) | 2018-04-26 | — | — | US | disclosed |
| US-20170319573-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | MERRIMACK PHARMACEUTICALS, INC. | 2017-11-09 | — | — | US | disclosed |
| WO-2017066726-A1 | STABILIZING CAMPTOTHECIN PHARMACEUTICAL COMPOSITIONS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296484-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-20190105317-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-12059497-B2 | Stabilizing camptothecin pharmaceutical compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-20190262331-A9 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-20200069586-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-20180110771-A1 | Liposomal Irinotecan Preparations | PHOSPHO1, PCTP, LCLAT1 | FGF1 4496/4885FGF2 4156/4885HPSE 1103/4885 |
| US-10456360-B2 | Stabilizing camptothecin pharmaceutical compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-20250152578-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4548/4885FGF2 4235/4885HPSE 1859/4885 |
| US-20230108934-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-20200179371-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-20210205219-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-20250000796-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4530/4885FGF2 4229/4885HPSE 1857/4885 |
| US-20210228567-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
| US-20170319573-A1 | Stabilizing Camptothecin Pharmaceutical Compositions | PHOSPHO1, PCTP, PLTP | FGF1 4526/4885FGF2 4261/4885HPSE 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.